ClinicalTrials.gov
ClinicalTrials.gov Menu

Pressure Support During Chest Wall Compression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01155648
Recruitment Status : Completed
First Posted : July 2, 2010
Last Update Posted : July 2, 2010
Sponsor:
Information provided by:
Hospital de Clinicas de Porto Alegre

Brief Summary:
The purpose of this study is to compare two physiotherapy techniques: chest wall compression versus chest wall compression plus increase of 10 cmH2O in inspiratory pressure.

Condition or disease Intervention/treatment Phase
Respiration, Artificial Critical Care Device: Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest. Device: Chest wall compression for ten minutes in chest Not Applicable

Detailed Description:
  1. After being placed in the supine position in bed, with head angle elevation at 30°, patients were randomized to:group 1 (G1): chest wall compression for ten minutes in chest or group 2 (G2): chest wall compression plus increase of 10 cmH2O in IP in PSV for ten minutes in chest.
  2. Clinical variables and APACHE II were registered.
  3. Parameters analyzed at the beginning (1) and at the end (2) of the protocol were: variation of peak pressure (ΔPp=Pp2-Pp1),variation of tidal volume (ΔVT =VT2-VT1), variation of dynamic compliance (ΔCdyn= Cdyn2-Cdyn1).
  4. The amount of variation of mucus secretion aspirated (ΔSa= Sa2-Sa1) at the end was also measured

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Increasing Pressure Support During Chest Wall Compression is Useful During Respiratory Therapy?
Study Start Date : May 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : May 2010

Arm Intervention/treatment
Experimental: PSV group.
Chest wall compression plus increase of 10 cmH2O of PSV.
Device: Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.
Active Comparator: chest wall compression group
Chest wall compression
Device: Chest wall compression for ten minutes in chest



Primary Outcome Measures :
  1. Variation of mucus secretion aspirated. [ Time Frame: Two years ]

Secondary Outcome Measures :
  1. Hemodynamic and pulmonary parameters. [ Time Frame: Two years ]
    The hemodynamic and pulmonary parameters were collected: Hart rate (HH), respiratory rate (f), mean arterial pressure (MAP) and peripheral arterial saturation of oxygen (SpO2); peak inspiratory pressure (Ppeak),and Tidal volume (VT) measured in the ventilator, dynamic compliance (Cdyn calculated through the formula VT/ Ppeak - PEEP)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients on mechanical ventilation over 48 hours
  • With ventilatory drive
  • Hemodynamically stable MAP> 60 mmHg
  • With treatment of respiratory therapy

Exclusion Criteria:

  • Contra indication of increased positive inspiratory pressure
  • Peak pressure in the upper airway > 40 cmH2O
  • Osteoporosis diagnosis
  • Deny to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01155648


Locations
Brazil
Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
Sponsors and Collaborators
Hospital de Clinicas de Porto Alegre
Investigators
Principal Investigator: Silvia R Vieira, PhD Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre